Melanoma Clinical Trials in Cleveland

Showing 161-180 of 306 trials

Study of the CD40 Agonistic Monoclonal Antibody APX005M

NCT02482168

This study is a phase 1 open-label dose escalation study of the immuno-activating monoclonal antibody APX005M in adults with solid tumors. Study is intended to establish the maximum tolerated dose and the overall safety and tolerability of APX005M in 3 different administration schedules.

CancerNSCLCMelanoma+3 more

Apexigen America, Inc.43 participantsStarted May 2015

Duarte, California, United States • Cleveland, Ohio, United States • Philadelphia, Pennsylvania, United States

COMPLETEDPhase 2< 1 mile

PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma

NCT00049530

RATIONALE: Peginterferon (PEG-interferon) alfa-2b may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of PEG-interferon alfa-2b in treating patients who have stage IV melanoma.

Melanoma (Skin)

Eastern Cooperative Oncology Group32 participantsStarted Jan 2004

Birmingham, Alabama, United States • Lakeland, Florida, United States • Bloomington, Illinois, United States +29 more locations

Study of the CD40 Agonistic Monoclonal Antibody APX005M

PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma

Melanoma Trials in Other Cities

Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma

Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma

Safety Study of SEA-CD40 in Cancer Patients

Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence

HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma

Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors

Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors

Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors

Study of ASN003 in Subjects With Advanced Solid Tumors

A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma

A Study of ADXS-NEO Expressing Personalized Tumor Antigens

Diagnostic Imaging Study for the Melanoma Advanced Imaging Dermatoscope (mAID)

Other Conditions in Cleveland